September 16, 2010 |
In a rebuke of the Abbott Laboratories diet drug Meridia, eight of 16 members of a Food and Drug Administration advisory panel said Wednesday that the drug should be withdrawn from the U.S. market. Six of the panelists said the drug should be prescribed only by "specially trained physicians. " The other two panelists said a new black box warning should be added to alert doctors to the increased risks of heart attacks and the need for closer monitoring of patients' blood pressure, pulse and body weight.
September 1, 2010 |
The prescription diet drug sibutramine, sold under the brand name Meridia, should be taken off the market because it raises the risk of heart attacks and strokes in some patients, the editor of the New England Journal of Medicine said Wednesday. Those risks, published in January on a government clinical-trials website and now in full in the journal, outweigh the modest benefits of the medication, said Dr. Gregory D. Curfman, the journal's executive editor and lead author of an editorial that accompanied the study.
August 30, 2009 |
The Food and Drug Administration is investigating reports of liver damage in patients taking alli, the only nonprescription weight-loss drug approved by the agency. Regulators say they have received more than 30 reports of liver damage in patients taking alli and Xenical, the prescription version of the drug. The reports, between 1999 and October 2008, included 27 hospitalized patients and six who suffered liver failure. Alli and Xenical are marketed by British drug maker GlaxoSmithKline, although Xenical is manufactured by the Swiss firm Roche.
October 24, 2005 |
Drugstore shelves are brimming with shakes, herbs and other products to facilitate weight loss -- but the vast majority of them have not been shown to work. It's possible that a proven medication that helps modestly with weight loss may join their ranks next year. The pharmaceutical company GlaxoSmithKline has asked the Food and Drug Administration for permission to sell a low-dose version of its diet drug Xenical over the counter.
August 27, 2002 |
Roche Holding, which is trying to revive demand for its Xenical obesity pill, said the medicine may delay or prevent the development of the most common form of diabetes. Patients taking Xenical who also made lifestyle changes reduced their risk of developing diabetes by 37%, a four-year study sponsored by Roche showed. Switzerland's second-biggest drug maker has changed its marketing for the pill and now offers three months of the medicine free to U.S. patients who purchase three months' worth.
May 15, 1998 |
The Food and Drug Administration is one step away from approving a new kind of diet drug, provided its manufacturer can clear up concerns about the drug's possible link to breast cancer. The drug, Xenical (pronounced ZEN-i-cal), could be the much-sought successor to the popular diet drug combination known as fen-phen, which all but ended when one of the two drugs in its potent formula was pulled from the market in September after being linked to potentially life-threatening heart valve problems.